Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Symtuza

ApprovedSmall molecule

CChelsea and Westminster NHS Foundation Trust

Symtuza is one of 75 small molecule programs targeting HIV infection. It is currently in Approved.

2

Indications

5

Total Trials

0

Active Trials

74

Competitors

Pipeline

Status by Indication[3][1]

Indication

HIV InfectionActive, not recruiting

NeurotoxicityActive, not recruiting

HIV InfectionPhase 3

Active, not recruiting

NeurotoxicityApproved

Active, not recruiting

Competition

Competitive Landscape

326 competitors in HIV Infection

#DrugCompanyPhaseTrials

Leukine

Betaseron

PEG-Intron

Proleukin

IIovance Biotherapeutics, Inc.

Foscavir

NNational Institute of Allergy and Infectious Diseases (NIAID)

TWINRIX™

F/TAF

F/TDF

PTM SEMA

Symtuza

CChelsea and Westminster NHS Foundation Trust

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Treatment1 trial

The Late Presenter Treatment Optimisation Study

Completed·NNEAT ID Foundation·Phase 3·NCT03696160·447 enrolled

Weight Gain1 trial

Effect of Biktarvy & Symtuza on microRNAs in HIV and Correlation With Weight Gain

Unknown status·—·Phase 4·NCT05463783·30 enrolled

Neurotoxicity1 trial

A Clinical Trial to Evaluate the Reversibility of Abacavir/Lamivudine/Dolutegravir CNS-Related Neurotoxicity After Switching to Tenofovir/Alafenamide/Emtricitabine/Darunavir/Cobicistat (TAF/FTC/DRV/c)

Completed·FFundacion SEIMC-GESIDA·Phase 4·NCT03685500·78 enrolled

HIV infection1 trial

Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat'

Completed·CChelsea and Westminster NHS Foundation Trust·Phase 3·NCT04653194·36 enrolled

Unspecified1 trial

Integrase Regimen Switch to Symtuza to Increase Tolerability/Adherence (SYMita)

Terminated·MMidland Research Group, Inc.·Phase 4·NCT04240210·1 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Symtuza. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Symtuza compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Symtuza. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Chelsea and Westminster NHS Foundation Trust company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: CChelsea and Westminster NHS Foundation Trust

Related News